Intranasal delivery of polymer-anchored lipid nanoconstructs of artemether-lumefantrine in Plasmodium berghei ANKA murine model

Kaur, Ripandeep; Gorki, Varun; Singh, Guneet; Kaur, Ranjot; Katare, Om Prakash; Nirmalan, Niroshini; Singh, Bhupinder

doi:10.1016/j.jddst.2020.102114

Cited by 12 publications

(9 citation statements)

References 64 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Schematic flowchart of intranasal delivery of polymer-anchored lipid nanoconstructs of artemether-lumefantrine in Plasmodium berghei ANKA murine model. Reproduced with permission from ref . Copyright 2020 Elsevier.…”

Section: Chitosan-based Biomaterials For Drug Delivery Systemmentioning

confidence: 99%

Chitosan-Based Smart Biomaterials for Biomedical Applications: Progress and Perspectives

Budiarso,

Rini,

Tsalsabila

et al. 2023

ACS Biomater. Sci. Eng.

View full text Add to dashboard Cite

Over the past decade, smart and functional biomaterials have escalated as one of the most rapidly emerging fields in the life sciences because the performance of biomaterials could be improved by careful consideration of their interaction and response with the living systems. Thus, chitosan could play a crucial role in this frontier field because it possesses many beneficial properties, especially in the biomedical field such as excellent biodegradability, hemostatic properties, antibacterial activity, antioxidant properties, biocompatibility, and low toxicity. Furthermore, chitosan is a smart and versatile biopolymer due to its polycationic nature with reactive functional groups that allow the polymer to form many interesting structures or to be modified in various ways to suit the targeted applications. In this review, we provide an up-to-date development of the versatile structures of chitosan-based smart biomaterials such as nanoparticles, hydrogels, nanofibers, and films, as well as their application in the biomedical field. This review also highlights several strategies to enhance biomaterial performance for fast growing fields in biomedical applications such as drug delivery systems, bone scaffolds, wound healing, and dentistry.

show abstract

Section: Chitosan-based Biomaterials For Drug Delivery Systemmentioning

confidence: 99%

Chitosan-Based Smart Biomaterials for Biomedical Applications: Progress and Perspectives

Budiarso,

Rini,

Tsalsabila

et al. 2023

ACS Biomater. Sci. Eng.

View full text Add to dashboard Cite

show abstract

“…Poloxamer can reduce mucus viscosity and elasticity, and, thereby, increase the transcellular transport of SLNs and NLCs [ 61 ]. Some mucoadhesive polymers, such as chitosan (CS) [ 63 ], trimethylchitosan [ 64 ], and glycol chitosan [ 29 ], can prolong the residence times of SLNs and NLCs in the nasal cavity. It was demonstrated in one study that a coating layer of polyethylene glycol 25 stearate inhibited P-glycoprotein efflux at cerebrovascular endothelial cell membranes, and thereby increased brain drug concentration [ 65 ].…”

Section: Nose-to-brain Delivery Pathways and Feasibilities Of Slns An...mentioning

confidence: 99%

“…Depending on drug and disease studies, appropriate animal models are selected to compare SLN or NLC candidates with free drugs or commercial products (administered IN, IV, or orally). For example, Plasmodium berghei ANKA-injected mice are used to evaluate the anti-cerebral malarial effects of artesunate [ 57 ], artemether, and lumefantrine [ 64 ]. In epilepsy, the maximal electroshock seizure model [ 79 , 80 , 81 ] or pentylenetetrazole-induced epilepsy rat model [ 82 , 83 , 84 ] are used.…”

Section: In Vivo Evaluation Of Intranasal Formulations For Nose-to-br...mentioning

confidence: 99%

“…Some studies used drug concentrations in the brain for comparison purposes. For example, artemether and lumefantrine were co-loaded in N,N,N-trimethyl chitosan-coated NLCs (TMC-NLCs) for the treatment of cerebral malaria [ 64 ]. In mice, TMC-NLCs (IN) produced higher drug concentrations in the brain than the drug suspension (IN and oral).…”

Section: In Vivo Evaluations Of Sln and Nlc-based Formulations For No...mentioning

confidence: 99%

“…In addition, DTE%, DTP%, logRDTE%, logRDTP%, B% IN/IV , and RB% values of GC-NLCs (IN) were higher than those for NLCs (IN) [ 28 ], which indicated that the glycol CS coating effectively increased brain targeting of NLCs. A recent study reported the efficacy of NLCs and TMC-NLCs co-loaded with artemether and lumefantrine [ 64 ]. It was found that TMC-NLCs (IN) exhibited greater parasite suppression than NLCs (IN) (95% vs. 82.5%) in parasite-injected mice.…”

Section: Effects Of Gelling Systems and Surface Modifications Of Slns...mentioning

confidence: 99%

See 2 more Smart Citations

Pharmacokinetics and Pharmacodynamics of Intranasal Solid Lipid Nanoparticles and Nanostructured Lipid Carriers for Nose-to-Brain Delivery

Nguyen

Maeng

2022

Pharmaceutics

View full text Add to dashboard Cite

Nose-to-brain drug delivery has been of great interest for the treatment of many central nervous system (CNS) diseases and psychiatric disorders over past decades. Several nasally administered formulations have been developed to circumvent the blood-brain barrier and directly deliver drugs to the CNS through the olfactory and trigeminal pathways. However, the nasal mucosa’s drug absorption is insufficient and the volume of the nasal cavity is small, which, in combination, make nose-to-brain drug delivery challenging. These problems could be minimized using formulations based on solid lipid nanoparticles (SLNs) or nanostructured lipid carriers (NLCs), which are effective nose-to-brain drug delivery systems that improve drug bioavailability by increasing drug solubility and permeation, extending drug action, and reducing enzymatic degradation. Various research groups have reported in vivo pharmacokinetics and pharmacodynamics of SLNs and NLCs nose-to-brain delivery systems. This review was undertaken to provide an overview of these studies and highlight research performed on SLN and NLC-based formulations aimed at improving the treatment of CNS diseases such neurodegenerative diseases, epilepsy, and schizophrenia. We discuss the efficacies and brain targeting efficiencies of these formulations based on considerations of their pharmacokinetic parameters and toxicities, point out some gaps in current knowledge, and propose future developmental targets.

show abstract

Solid Lipid Nanoparticles in Malaria

Paliwal

Prajapati

Parihar

et al. 2023

Malarial Drug Delivery Systems

View full text Add to dashboard Cite

Intranasal delivery of polymer-anchored lipid nanoconstructs of artemether-lumefantrine in Plasmodium berghei ANKA murine model

Cited by 12 publications

References 64 publications

Chitosan-Based Smart Biomaterials for Biomedical Applications: Progress and Perspectives

Chitosan-Based Smart Biomaterials for Biomedical Applications: Progress and Perspectives

Pharmacokinetics and Pharmacodynamics of Intranasal Solid Lipid Nanoparticles and Nanostructured Lipid Carriers for Nose-to-Brain Delivery

Solid Lipid Nanoparticles in Malaria

Contact Info

Product

Resources

About